Charm Sciences, Inc.

Galectin Therapeutics, Inc.

Galectin Sciences, LLC

Providence Health & Services - Oregon

Galeotin Therapeutics, Inc.

Boston Therapeutics, Inc.

Eliezer Zomer

Anatole A Klyosov

Peter G Traber

Stanley E Charm

Richard T Skiffington

Elena Chekhova

Steven J Saul

David C Platt

Robert J Markovsky

Joseph M Johnson

Sharon Shechter

Raphael Nir

Ryan George

Max Gandman

Paul R Donahue

Yael Agi Glickman

Joan L Scheemaker

Shefali B Trivedi

William L Redmond

Stefanie N Linch

Thomas Lieu

Cheryl A Boyer

Steven Marc Landau

Cheryl B Francisco

Shlomo Capua

Lea Gandman

Lee Gandman

Kenneth T Sabin

Shifali B Trivedi

Yael Agi-Glickman

Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.

Compounds for the prevention and treatment of medical disorders and uses thereof

Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

Compounds for the prevention and treatment of diseases and the use thereof

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Methods for treatment of arthritis

Composition of novel carbohydrate drug for treatment of human diseases

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-&#x3b2;1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.

Method for enhancing specific immunotherapies in cancer treatment

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-&#x3b1;-L-arabinose (Ara) residues.

Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.

Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

Compositions of novel carbohydrate drug for treatment of human diseases

Growing community of inventors

Newton, MA, United States of America

Eliezer Zomer